DC-ATA

DC-ATA Uses, Dosage, Side Effects, Food Interaction and all others data.

DC-ATA is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).

The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.

The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.

Trade Name DC-ATA
Generic AV-COVID-19
AV-COVID-19 Other Names DC-ATA, DCV
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
DC-ATA
DC-ATA

Innovators Monograph

You find simplified version here DC-ATA


*** Taking medicines without doctor's advice can cause long-term problems.
Share